Cunha Joanne Szczygiel, Gilek-Seibert Katarzyna
Division of Rheumatology, The Warren Alpert Medical School of Brown University, Rhode Island Hospital and the Providence Veterans Affairs Medical Center.
Division of Rheumatology, Roger Williams Medical Center, Providence, RI; Boston University School of Medicine.
R I Med J (2013). 2016 Dec 1;99(12):23-27.
Systemic lupus erythematosus (SLE) is a chronic, complicated and challenging disease to diagnose and treat. The etiology of SLE is unknown, but certain risk factors have been identified that lead to immune system dysfunction with antibody formation and immune complex deposition. This immune system dysregulation causes organ injury, contributing to the variable manifestations and relapsing-remitting course of the disease. Criteria were created to aide in the diagnosis, focusing on clinical manifestations and antibody profiles specific to SLE. Treatment options are limited to a few medications to control the inflammation and decrease organ damage. Continuing investigations into the pathogenesis of SLE has led to new discoveries, making more medications available to treat this difficult disease. [Full article available at http://rimed.org/rimedicaljournal-2016-12.asp].
系统性红斑狼疮（SLE）是一种诊断和治疗都很复杂且具有挑战性的慢性疾病。SLE的病因尚不清楚，但已确定某些危险因素会导致免疫系统功能障碍，进而形成抗体和免疫复合物沉积。这种免疫系统失调会导致器官损伤，从而造成该疾病多种多样的表现以及复发-缓解病程。已制定了相关标准来辅助诊断，重点关注SLE特有的临床表现和抗体谱。治疗选择仅限于少数几种药物，用于控制炎症和减少器官损伤。对SLE发病机制的持续研究带来了新发现，使得更多药物可用于治疗这种疑难疾病。[全文可在http://rimed.org/rimedicaljournal-2016-12.asp获取]
